THOR 809
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2021 (NCT05876767)
Timeline
Indications
Mechanism of action
- Interleukin-2MODULATOR
IL2 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07156175 | Phase 2 | Oct 14, 2025 | Sanofi |
| NCT05876767 | Phase 1 | Oct 15, 2021 | Sanofi |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 2 | 2 | 2021 |
1 organizations
Page 1 / 1